Table 3: Efficacy rates and duration of response associated with different chemotherapy regimens for ASTS.

Probability of achieving:Median duration of response (months) in:
Complete remissionPartial remissionStable diseaseProgressive diseaseComplete remissionPartial remissionStable disease

First-line treatments
 Doxorubicin/ifosfamide0.060.210.380.3515.447.696.41
[16, 17, 2232][16, 17, 2232][16, 17, 2232][16, 17, 2232][16, 17, 22, 24, 27, 28, 31, 33][16, 17, 22, 24, 27, 28, 31, 33][16, 17, 22, 24, 27, 28, 31, 33]
 Trabectedin0.03 0.11 0.14 0.72 17.74 8.75 7.48
[34][34][34][34][34][34][34]
Second-line treatments
 CYVADIC*∧0.030.190.390.3912.136.575.75
 Docetaxel0.00 0.11 0.25 0.64 0.006.60 7.17
[3537][3537][3537][3537] [35, 36][35, 36] [35, 36]
 Doxorubicin0.02 0.07 0.31 0.6112.13* 6.57* 5.75* 
[38, 39][38, 39][38, 39] [38, 39]
 Doxorubicin/ifosfamide0.050.27 0.37 0.31 12.13* 6.57* 5.75*
[22, 38][22, 38][22, 38][22, 38]
 Gemcitabine0.00 0.08 0.33 0.59 0.00 4.46 3.86
[4045][4045][4045][4045][43, 46, 47][43, 46, 47][43, 46, 47]
 Gemcitabine/dacarbazine0.01 0.10 0.39 0.51 10.48 6.50 5.79
[4850][4850][4850][4850][48][48][48]
 Gemcitabine/docetaxel0.05 0.190.410.35 12.13* 6.57* 5.75* 
[40, 5154] [40, 5154] [40, 5154][40, 5154]
 Gemcitabine/paclitaxel*0.030.190.390.3912.136.57 5.75
 Gemcitabine/vinorelbine0.02 0.10 0.10 0.78 16.10 16.109.60
[55, 56][55, 56][55, 56][55, 56][56] [56][56]
 Ifosfamide0.02 0.130.24 0.61 13.77 8.75 7.61
[38, 5760] [38, 5760][38, 5760][38, 5760][58, 60][58, 60][58, 60]
 Ifosfamide/epirubicin*0.050.270.370.3112.136.575.75
 Liposomal doxorubicin*0.020.070.310.6112.136.575.75
 Trabectedin<0.01 0.070.440.4916.1410.258.91
[19, 34, 6167][19, 34, 6167][19, 34, 6167][19, 34, 6167][19, 34, 61, 6365][19, 34, 61, 6365][19, 34, 61, 6365]
 Trofosfamide0.00 0.03 0.19 0.7912.13*6.57*5.75*
[6870][6870][6870] [6870]
 Trofosfamide/etoposide*0.030.190.390.3912.136.575.75

 *Values were estimated. CYVADIC: cyclophosphamide, vincristine, adriamycin and dacarbazine.